Clinical trials: Clonal Hematopoiesis of Indeterminate Potential
ST-elevation Myocardial Infarction (STEMI), Clonal Hematopoiesis of Indeterminate Potential (CHIP)
Clonal Hematopoiesis of Indeterminate Potential and Infarct Severity in ST-Elevation Myocardial Infarction
Clonal Hematopoiesis of Indeterminate Potential (CHIP) refers to the age-related expansion of hematopoietic stem cell clones carrying somatic mutations in leukemia-associated driver genes (e.g., DNMT3A, TET2, ASXL1) in the…
- Trial name
- CHIP in STEMI (NCT07615023)
- Testing
- Clonal hematopoiesis assessment and cardiac magnetic resonance imaging
- Where
- Austria
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Medical University Innsbruck
Colchicine, Coronary Atherosclerosis Management
Precision Colchicine Intervention to Suppress Atherosclerosis in TET2 Clonal Hematopoiesis
This study aims to investigate whether TET2-associated clonal hematopoiesis of indeterminate potential (TET2-CHIP) can serve as a biomarker to guide precision use of colchicine in a population of clinically stable post-ACS…
- Conditions
- Colchicine, Coronary Atherosclerosis Management, Clonal Hematopoiesis of Indeterminate Potential
- Trial name
- NCT07362966
- Testing
- Colchicine 0.5 mg orally once daily for 12 months., SoC therapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shenyang Northern Hospital
Clonal Hematopoiesis of Indeterminate Potential, Clonal Cytopenia of Undetermined Significance
CHIP/CCUS Natural History Protocol
Background: Clonal Hematopoiesis of Indeterminate Potential (CHIP) is a change in a person s DNA that can increase a person s risk of developing blood cancers or cardiovascular disease. CHIP occurs mostly occurs in older people.
- Trial name
- NCT04102423
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Clonal Hematopoiesis, Clonal Hematopoiesis of Indeterminate Potential
CHIP in Health and Disease
Clonal hematopoiesis (CH), including clonal hematopoiesis of indeterminate potential (CHIP), is an age-associated condition characterized by the expansion of hematopoietic stem and progenitor cell clones carrying acquired somatic…
- Conditions
- Clonal Hematopoiesis, Clonal Hematopoiesis of Indeterminate Potential, Clonal Cytopenia of Undetermined Significance (CCUS), Myelodysplastic Syndrome
- Trial name
- CHIP2 (NCT07780552)
- Where
- Austria
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- VASCage GmbH
Clonal Hematopoiesis of Indeterminate Potential, Monoclonal Gammopathy
Pre-malignant States to Hematologic Malignancies in Firefighters
The purpose of the study is to evaluate if firefighter exposure to hazardous compounds will increase the incidence of premalignant hematological states which subsequently increases the risk of the development of hematologic…
- Conditions
- Clonal Hematopoiesis of Indeterminate Potential, Monoclonal Gammopathy, Non Hodgkin Lymphoma, Leukemia
- Trial name
- NCT06870760
- Testing
- Monoclonal Gammopathy, Complete Blood Count with differential (CBC w/ diff), Clonal hematopoiesis (CHIP)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Lung Cancer (Diagnosis), Osteochondroma
Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
The goal of the Clonal Hematopoiesis Chemotherapy and Radiation Effects (CH CARE) Study is to understand how the presence or absence of clonal hematopoiesis (CH) influences outcomes in people receiving chemotherapy and radiation…
- Conditions
- Lung Cancer (Diagnosis), Osteochondroma, Spitz Nevus, Solid Cancers
- Trial name
- CH CARE (NCT07675967)
- Testing
- Samples
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- Dana-Farber Cancer Institute
Coronary Heart Disease, Clonal Hematopoiesis of Indeterminate Potential (CHIP)
A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
This Phase 2a clinical trial evaluated the effectiveness, safety, and tolerability of increasing dose strengths of an oral daily medication, DFV890, administered for 12 weeks, or a single s.c.
- Trial name
- NCT06097663
- Testing
- MAS825, DFV890
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis, Osteoarthritis, Hip
Metabolic Profiling of Hematopoietic Stem Cells in Clonal Hematopoiesis (CHIP)
Bone marrow samples will be collected from patients undergoing hip arthroplasty surgery. Blood and bone marrow samples will be used for metabolic profiling and analysis of relevant CHIP mutations.
- Conditions
- Osteoporosis, Osteoarthritis, Hip, Hip Fractures, Clonal Hematopoiesis of Indeterminate Potential
- Trial name
- NCT05246813
- Testing
- Blood and bone marrow cell collection
- Where
- Belgium
- Volunteers
- 24 people
- Sponsor
- Imelda Hospital, Bonheiden
Immune System Diseases, Autoimmune Diseases
Clonal Hematopoiesis of Immunological Significance
Ambispective, national, multicenter observational cohort study aimed at characterizing the satellite dysimmune manifestations of clonal hematopoiesis, including Vexas (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic)…
- Conditions
- Immune System Diseases, Autoimmune Diseases, Inflammation, Autoinflammatory Diseases
- Trial name
- CHIS (NCT05969821)
- Testing
- observational cohort study
- Where
- France
- Volunteers
- 5,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Myeloid Malignancy, Inherited Bone Marrow Failure Syndrome
Pre-myeloid Cancer and Bone Marrow Failure Clinic Study
This clinical trial tests next generation sequencing (NGS) for the detection of precursor features of pre-myeloid cancers and bone marrow failure syndromes.
- Conditions
- Myeloid Malignancy, Inherited Bone Marrow Failure Syndrome, Clonal Expansion, Cytopenia
- Trial name
- NCT02958462
- Testing
- Biospecimen Collection, Bone Marrow Biopsy, Punch Biopsy
- Where
- 3 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Mayo Clinic
ACS, Clonal Hematopoiesis of Indeterminate Potential
CHIP and Residual Cardiovascular Event Tendency After Smoking Cessation
In order to identify the association between clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular risks after smoking cessation, this study intends to recruit ACS patients undergoing complete…
- Conditions
- ACS, Clonal Hematopoiesis of Indeterminate Potential, Smoking Cessation
- Trial name
- CHIP-RETENTION (NCT04987268)
- Testing
- clonal hematopoiesis of indeterminate potential
- Where
- China
- Volunteers
- 1,029 people
- Sponsor
- Shenyang Northern Hospital
Venous Thromboses, Thromboembolic Disease
Clonal Hematopoiesis and NETs Formation in Venous Thrombosis (CLODETTE)
Thrombo-embolic venous diseases are represented by deep venous thrombosis and/or pulmonary embolism. In some patients with repeated thrombosis or occurrence of thrombosis in unusual sites, the etiological workup remains negative…
- Conditions
- Venous Thromboses, Thromboembolic Disease, Neutrophil Extracellular Trap Formation, Clonal Hematopoiesis of Indeterminate Potential
- Trial name
- CLODETTE (NCT05711173)
- Testing
- Additional blood sampling
- Where
- 7 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Bordeaux
Giant Cell Arteritis, Temporal Arteritis
Clonal Hematopoiesis in Giant Cell Arteritis
The goal of this clinical trial is to verify whether CHIP is correlated with the clinical, instrumental, and histological characteristics of GCA, and to characterize the pathogenetic effects of clonal hemopoiesis on vasculitis.
- Conditions
- Giant Cell Arteritis, Temporal Arteritis, Clonal Hematopoiesis of Indeterminate Potential, Horton Disease
- Trial name
- CH-GCA (NCT06244069)
- Testing
- Temporal arterial biopsy, Whole exome sequencing, Single cell transcriptomics
- Volunteers
- 326 people, healthy volunteers welcome
- Sponsor
- ASST Fatebenefratelli Sacco